Skip to content

Welcome to Discover Pharma! Today is : October 13, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

oncology

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    FDA grants Fast Track status to SOTIO’s colorectal cancer ADC ahead of Phase 1/2 trial

    The US FDA has granted Fast Track Designation to SOTIO [...]

    July 14, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Poolbeg Pharma doses first patient in POLB 001 trial to prevent cytokine release syndrome

    Poolbeg Pharma has dosed the first patient in a clinical [...]

    July 13, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    FORE Biotherapeutics completes enrolment in registrational plixorafenib brain tumour study

    FORE Biotherapeutics has completed target enrolment in the primary central [...]

    July 8, 2026
  • Clinical & Regulatory,Digital & Data,Research & Development

    Study quantifies financial benefits of risk-based quality management in oncology trials

    A peer-reviewed study published in Therapeutic Innovation & Regulatory Science [...]

    July 8, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Ananda Pharma begins Phase 2 trial of cannabidiol therapy for chemotherapy nerve damage

    Ananda Pharma has begun participant screening for a Phase 2 [...]

    July 6, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Novartis agrees $1.5bn Myricx Bio acquisition to strengthen ADC pipeline

    Novartis has agreed to acquire UK biotech Myricx Bio for [...]

    July 6, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    FDA backs Telix Phase 3 ProstACT trial expansion into US

    Telix Pharmaceuticals has received FDA agreement on the protocol and [...]

    July 3, 2026
  • Advanced Therapies,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Lonza expands HPAPI capacity to support ADC manufacturing

    Lonza will expand its highly potent active pharmaceutical ingredient manufacturing [...]

    July 2, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends cemiplimab for recurrent or metastatic cervical cancer

    NICE has recommended cemiplimab for eligible adults with recurrent or [...]

    June 24, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics

    InduPro licenses Lonza ADC technology for oncology programmes

    InduPro has licensed Lonza’s antibody-drug conjugate technologies to support development [...]

    June 22, 2026
Previous234Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Andelyn to manufacture FDA-approved Fayuvi gene therapy for Sanfilippo syndrome
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Ariadne Bio launches with Parkinson’s apathy drug candidate
    Categories: Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • MaaT Pharma to advance Phase 3 trial after EMA rejects MaaT013 application
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top